NeuroBo Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own33.77% Shs Outstand26.66M Perf Week-2.79%
Market Cap15.13M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float10.34M Perf Month-28.63%
Income-14.80M PEG- EPS next Q- Inst Own32.50% Short Float2.31% Perf Quarter-31.81%
Sales- P/S- EPS this Y63.90% Inst Trans-3.57% Short Ratio1.23 Perf Half Y-67.01%
Book/sh0.45 P/B1.13 EPS next Y- ROA-121.00% Target Price16.00 Perf Year-82.18%
Cash/sh0.39 P/C1.30 EPS next 5Y- ROE-140.90% 52W Range0.41 - 6.57 Perf YTD-58.36%
Dividend- P/FCF- EPS past 5Y60.00% ROI- 52W High-92.27% Beta0.68
Dividend %- Quick Ratio8.90 Sales past 5Y- Gross Margin- 52W Low22.88% ATR0.07
Employees5 Current Ratio8.90 Sales Q/Q- Oper. Margin- RSI (14)36.80 Volatility10.87% 14.98%
OptionableYes Debt/Eq0.00 EPS Q/Q29.90% Profit Margin- Rel Volume0.24 Prev Close0.51
ShortableYes LT Debt/Eq0.00 EarningsApr 01 BMO Payout- Avg Volume194.36K Price0.51
Recom2.00 SMA20-7.66% SMA50-31.62% SMA200-70.05% Volume46,368 Change0.20%
Jun-15-20Initiated H.C. Wainwright Buy $20
May-06-22 08:00AM  
Apr-01-22 08:00AM  
Mar-15-22 08:00AM  
Jan-28-22 04:30PM  
Nov-15-21 08:00AM  
Nov-04-21 08:00AM  
Oct-13-21 08:00AM  
Oct-05-21 01:13PM  
Oct-01-21 08:00AM  
Sep-03-21 11:27AM  
Aug-16-21 08:00AM  
Jul-12-21 08:30AM  
May-17-21 05:02PM  
Apr-15-21 04:52PM  
Mar-24-21 08:00AM  
Mar-05-21 08:30AM  
Jan-21-21 04:05PM  
Jan-19-21 08:00AM  
Jan-06-21 08:30AM  
Dec-21-20 05:08AM  
Nov-13-20 04:30PM  
Sep-02-20 08:30AM  
Aug-11-20 03:00PM  
Jun-16-20 04:05PM  
May-26-20 08:30AM  
May-20-20 04:29PM  
Apr-21-20 08:30AM  
Apr-16-20 04:22PM  
Apr-14-20 09:15AM  
Mar-31-20 11:04AM  
Mar-30-20 04:30PM  
Jan-13-20 09:00AM  
Jan-10-20 05:00PM  
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.